 Chemical Structure.png)
Purvalanol B (formerly known as NG-95) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, inhibiting Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively.
Physicochemical Properties
| Molecular Formula | C20H25CLN6O3 |
| Molecular Weight | 432.909 |
| Exact Mass | 432.167 |
| Elemental Analysis | C, 55.49; H, 5.82; Cl, 8.19; N, 19.41; O, 11.09 |
| CAS # | 212844-54-7 |
| Related CAS # | Purvalanol A;212844-53-6;(S)-Purvalanol B;2310135-61-4 |
| PubChem CID | 448991 |
| Appearance | White to off-white solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 660.6±65.0 °C at 760 mmHg |
| Flash Point | 353.3±34.3 °C |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.673 |
| LogP | 2.42 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 30 |
| Complexity | 583 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | ClC1=C(C(=O)O[H])C([H])=C([H])C(=C1[H])N([H])C1=C2C(=NC(=N1)N([H])[C@@]([H])(C([H])([H])O[H])C([H])(C([H])([H])[H])C([H])([H])[H])N(C([H])=N2)C([H])(C([H])([H])[H])C([H])([H])[H] |
| InChi Key | ZKDXRFMOHZVXSG-HNNXBMFYSA-N |
| InChi Code | InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1 |
| Chemical Name | 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid |
| Synonyms | NG 95; NG-95; NG95; Purvalanol B |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | cdc2/cyclin B (IC50 = 6 nM); cdk2/cyclin A (IC50 = 6 nM); CDK2/cyclinE (IC50 = 9 nM); CDK5/p35 (IC50 = 6 nM) |
| ln Vitro | Purvalanol B inhibits the growth of a chloroquine-resistant strain of P. falciparum (FCR-3) with an IC50 of 7.07 μM by binding to P. falciparum casein kinase 1 (CK1) from blood stage cell lysates[1]. |
| References |
[1]. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8. [2]. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar J. 2015 Apr 8;14:147. |
| Additional Infomation | Purvalanol B is a purvalanol. It has a role as a protein kinase inhibitor. |
Solubility Data
| Solubility (In Vitro) |
DMSO: ~86 mg/mL (198.7 mM) Ethanol: ˂1 mg/mL Water: ˂1 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3099 mL | 11.5497 mL | 23.0995 mL | |
| 5 mM | 0.4620 mL | 2.3099 mL | 4.6199 mL | |
| 10 mM | 0.2310 mL | 1.1550 mL | 2.3099 mL |